PL369670A1 - Combinations comprising epothilones and anti-metabolites - Google Patents
Combinations comprising epothilones and anti-metabolitesInfo
- Publication number
- PL369670A1 PL369670A1 PL03369670A PL36967003A PL369670A1 PL 369670 A1 PL369670 A1 PL 369670A1 PL 03369670 A PL03369670 A PL 03369670A PL 36967003 A PL36967003 A PL 36967003A PL 369670 A1 PL369670 A1 PL 369670A1
- Authority
- PL
- Poland
- Prior art keywords
- epothilones
- metabolites
- combinations
- Prior art date
Links
- 230000000340 anti-metabolite Effects 0.000 title 1
- 229940100197 antimetabolite Drugs 0.000 title 1
- 239000002256 antimetabolite Substances 0.000 title 1
- 229930013356 epothilone Natural products 0.000 title 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34862202P | 2002-01-14 | 2002-01-14 | |
| US41617302P | 2002-10-04 | 2002-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL369670A1 true PL369670A1 (en) | 2005-05-02 |
Family
ID=26995808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03369670A PL369670A1 (en) | 2002-01-14 | 2003-01-13 | Combinations comprising epothilones and anti-metabolites |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20060089327A1 (enExample) |
| EP (2) | EP1469847A1 (enExample) |
| JP (1) | JP2005513167A (enExample) |
| KR (1) | KR20040078123A (enExample) |
| CN (1) | CN1615136A (enExample) |
| AU (1) | AU2003235761A1 (enExample) |
| BR (1) | BR0306861A (enExample) |
| CA (1) | CA2471509A1 (enExample) |
| IL (1) | IL162595A0 (enExample) |
| MX (1) | MXPA04006822A (enExample) |
| NO (1) | NO20043279L (enExample) |
| NZ (1) | NZ533940A (enExample) |
| PL (1) | PL369670A1 (enExample) |
| RU (1) | RU2346686C2 (enExample) |
| TW (1) | TWI341728B (enExample) |
| WO (1) | WO2003057217A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1386922B1 (en) | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| ATE554756T1 (de) | 2001-03-14 | 2012-05-15 | Bristol Myers Squibb Co | Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen |
| EP1372650B1 (en) * | 2001-03-19 | 2008-11-19 | Novartis AG | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| BR0315169A (pt) * | 2002-10-09 | 2005-08-23 | Kosan Biosciences Inc | Referência cruzada a pedidos de patente relacionados |
| CN1870995A (zh) * | 2003-09-02 | 2006-11-29 | 诺瓦提斯公司 | 使用埃坡霉素的癌症治疗 |
| US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| CA2645633A1 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| CN101415411A (zh) * | 2006-04-05 | 2009-04-22 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂组合 |
| CA2927832C (en) | 2010-05-18 | 2021-03-23 | Cerulean Pharma Inc. | Cyclodextrin-containing polymer-therapeutic agent conjugates and their use |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US2705727A (en) | 1952-07-10 | 1955-04-05 | Du Pont | Synthesis of ureas |
| US2933498A (en) | 1954-12-28 | 1960-04-19 | Burroughs Wellcome Co | 7-aminothiazolo-(5,4-d) pyrimidine |
| US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
| US4393064A (en) | 1976-03-05 | 1983-07-12 | Sri International | Process and composition for treatment of leukemia and process for preparing the same |
| US4357324A (en) | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
| US4760135A (en) | 1984-09-06 | 1988-07-26 | University Of Kentucky Research Foundation | Phloretin and phlorizin derivative containing compounds |
| DE3587500T2 (de) * | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| DE3773716D1 (de) | 1986-03-24 | 1991-11-21 | Nippon Kayaku Kk | Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung. |
| DE69003670T2 (de) | 1989-01-05 | 1994-01-27 | Otsuka Pharma Co Ltd | Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs. |
| CA2087540C (en) * | 1991-05-27 | 1999-01-19 | Taiho Pharmaceutical Co., Ltd. | Composition, method and kit for potentiating antitumor activity and for curing tumor |
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| AU671491B2 (en) * | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
| ATE267197T1 (de) | 1996-11-18 | 2004-06-15 | Biotechnolog Forschung Gmbh | Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| KR20080016756A (ko) | 1998-02-05 | 2008-02-21 | 노파르티스 아게 | 유기화합물 함유 조성물 |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| CA2322157C (en) | 1998-02-25 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| CN100381566C (zh) | 1998-11-20 | 2008-04-16 | 科森生物科学公司 | 产生环氧噻酮及其衍生物的重组方法和材料 |
| BR9916833A (pt) * | 1998-12-22 | 2001-09-25 | Novartis Ag | Derivados de epotilona e seu uso como agentes antitumor |
| EE04852B1 (et) * | 1999-02-22 | 2007-06-15 | Gesellschaft Fuer Biotechnologische Forschung Mbh | C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel |
| ES2273688T3 (es) * | 1999-04-14 | 2007-05-16 | Dana-Farber Cancer Institute, Inc. | Procedimiento y composicion para el tratamiento de cancer. |
| GB9918429D0 (en) * | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
| US20020045609A1 (en) * | 2000-05-26 | 2002-04-18 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
| ATE554756T1 (de) * | 2001-03-14 | 2012-05-15 | Bristol Myers Squibb Co | Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen |
| TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
-
2003
- 2003-01-13 AU AU2003235761A patent/AU2003235761A1/en not_active Abandoned
- 2003-01-13 IL IL16259503A patent/IL162595A0/xx unknown
- 2003-01-13 JP JP2003557575A patent/JP2005513167A/ja not_active Ceased
- 2003-01-13 RU RU2004124943/15A patent/RU2346686C2/ru not_active IP Right Cessation
- 2003-01-13 CN CNA03802215XA patent/CN1615136A/zh active Pending
- 2003-01-13 EP EP20030729249 patent/EP1469847A1/en not_active Ceased
- 2003-01-13 US US10/501,207 patent/US20060089327A1/en not_active Abandoned
- 2003-01-13 CA CA002471509A patent/CA2471509A1/en not_active Abandoned
- 2003-01-13 WO PCT/EP2003/000232 patent/WO2003057217A1/en not_active Ceased
- 2003-01-13 PL PL03369670A patent/PL369670A1/xx unknown
- 2003-01-13 NZ NZ533940A patent/NZ533940A/en not_active IP Right Cessation
- 2003-01-13 KR KR10-2004-7010853A patent/KR20040078123A/ko not_active Ceased
- 2003-01-13 BR BR0306861-7A patent/BR0306861A/pt not_active Application Discontinuation
- 2003-01-13 EP EP08169239A patent/EP2030618A3/en not_active Withdrawn
- 2003-01-13 MX MXPA04006822A patent/MXPA04006822A/es active IP Right Grant
- 2003-01-13 TW TW092100606A patent/TWI341728B/zh not_active IP Right Cessation
-
2004
- 2004-08-05 NO NO20043279A patent/NO20043279L/no not_active Application Discontinuation
-
2009
- 2009-08-12 US US12/539,891 patent/US20090298791A1/en not_active Abandoned
-
2010
- 2010-12-13 US US12/966,575 patent/US20110082101A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL162595A0 (en) | 2005-11-20 |
| MXPA04006822A (es) | 2004-12-08 |
| US20110082101A1 (en) | 2011-04-07 |
| RU2004124943A (ru) | 2005-08-10 |
| AU2003235761A1 (en) | 2003-07-24 |
| CA2471509A1 (en) | 2003-07-17 |
| NO20043279L (no) | 2004-08-05 |
| EP2030618A2 (en) | 2009-03-04 |
| EP2030618A3 (en) | 2009-03-11 |
| US20090298791A1 (en) | 2009-12-03 |
| TWI341728B (en) | 2011-05-11 |
| EP1469847A1 (en) | 2004-10-27 |
| CN1615136A (zh) | 2005-05-11 |
| RU2346686C2 (ru) | 2009-02-20 |
| KR20040078123A (ko) | 2004-09-08 |
| BR0306861A (pt) | 2004-11-03 |
| NZ533940A (en) | 2007-06-29 |
| TW200306185A (en) | 2003-11-16 |
| US20060089327A1 (en) | 2006-04-27 |
| WO2003057217A1 (en) | 2003-07-17 |
| JP2005513167A (ja) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1539941A4 (en) | ADZYMES AND THEIR USES | |
| ZA200603882B (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | |
| IL175491A0 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides | |
| EP1575495A4 (en) | COMPOUNDS AND METHODS | |
| IL163868A0 (en) | Hermiasterlin derivatives and uses thereof | |
| GB0428391D0 (en) | Connection and connection part | |
| GB0220214D0 (en) | Compounds and their use | |
| SI1551805T1 (sl) | Substituirani gama-fenil-delta-laktami in njihova uporaba | |
| IL162595A0 (en) | Combinations comprising epothilones and antimetabolites | |
| IL165112A0 (en) | Variant integrinpolypeptides and thereof | |
| AU2003231827A8 (en) | Pseudo-tissues and uses thereof | |
| AU2003302173A8 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
| GB0220776D0 (en) | FOXP2 and uses thereof | |
| GB0230134D0 (en) | Compounds and their use | |
| HK1070294A (en) | Combinations comprising epothilones and anti-metabolites | |
| AU2003216442A8 (en) | Enkurin and uses thereof | |
| GB0230281D0 (en) | Compounds and their use | |
| GB0218031D0 (en) | Compounds and their use | |
| AU2003223357A8 (en) | Compounds and methods | |
| AU2003262008A1 (en) | Polynucleotide derivative and use thereof | |
| GB0220215D0 (en) | Compounds and their use | |
| SI1485090T1 (sl) | Kombinacija vključujoča derivat epotilona in imidazotetrazinon | |
| GB0329079D0 (en) | Method and use | |
| AU2003904521A0 (en) | Transfer method and arrangement | |
| GB0310240D0 (en) | Workframe and tools |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |